Kyverna Therapeutics, Inc.
KYTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $501.6M
$8.25
▼ -1.20%
P/E
-2.81
Mkt Cap
$501.6M
52-Wk Range
$3.72–$13.67
52-Week Range
$3.72 - $13.67
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 111.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CD19-targeted CAR T-cell platform technology
- Strategic partnerships with Intellia Therapeutics and Kite for R&D acceleration
- Multi-indication pipeline addressing high-unmet medical needs
- Clinical-stage programs with established proof-of-concept in autoimmune diseases
Bear Case
1 risk
- Above-average volatility (beta 2.0).
Growth
Stable outlook
Advancement of KYV-101 through Phase II clinical trials
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+10.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying KYTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.63 vs -$0.67 consensus (+6.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 4, 2026
vs Industry
How KYTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.